SGLT2 Inhibitors in Type 2 Diabetes Lowers Gout Risk Save
A recent study of drugs used in type 2 diabetes (T2DM) shows that SGLT2 inhibitors have a lower risk for gout compared with those receiving DPP4 inhibitors.
The sodium–glucose cotransporter-2 inhibitors (e.g., Invokana, Jardiance, Farxiga) are reported to lower the risk of gout in T2DM patient. Yet, the use of dipeptidyl peptidase-4 (DPP-4) inhibitors (e.g., Januvia, Trajenta) may cause arthralgia or arthritis, especially over time.
A study of the Taiwan nationwide insurance database showed an 11% risk reduction (HR, 0.89; 95% CI, 0.82-0.96) in the incidence of gout in 47 405 patients with type 2 diabetes who received an SGLT2 inhibitor, compared to a propensity score–matched cohort on DPP-4 inhibitors.
In T2DM patients SGLT2 inhibitors may be preferred as they have the potential to decrease the incidence of gout .